Tag: Lindquist Lab

Whitehead’s Susan Lindquist elected to UK’s Royal Society

May 1, 2015

The UK’s Royal Society today announced that it has elected Whitehead Institute’s Susan Lindquist as a Foreign Member.

Heat-shock protein enables tumor evolution and drug resistance in breast cancer

December 8, 2014

Long known for its ability to help organisms successfully adapt to environmentally stressful conditions, the highly conserved molecular chaperone heat-shock protein 90 (HSP90) also enables estrogen receptor-positive (ER+) breast cancers to develop resistance to hormonal therapy.  

Images of tissue sections from breast cancer patient biopsies

Master heat-shock factor supports reprogramming of normal cells to enable tumor growth and metastasis

July 31, 2014

Long associated with enabling the proliferation of cancer cells, the ancient cellular survival response regulated by Heat-Shock Factor 1 (HSF1) can also turn neighboring cells in their environment into co-conspirators that support malignant progression and metastasis.

Graph of growth curves of wild type and amyloid-beta strains treated with clioquinol

Yeast model reveals Alzheimer’s drug candidate and its mechanism of action

March 3, 2014

Whitehead Institute scientists have used a yeast cell-based drug screen to identify a class of molecules that target the amyloid-β (Aβ) peptide involved in Alzheimer’s disease (AD).  

Image comparing a surface form and cave form of the fish Astyanax mexicanus

Rapid evolution of novel forms: Environmental change triggers inborn capacity for adaptation

December 12, 2013

A team of researchers from Harvard Medical School and Whitehead Institute report that, at least in the case of one variety of cavefish, one agent of evolutionary change is the heat shock protein known as HSP90.

Microscope image of filamentation in Candida albicans with and without amphotericin B resistance

Understanding the evolution of drug resistance points to novel strategy for developing better antimicrobials

October 29, 2013

The most common fungal pathogen in humans, Candida albicans, rarely develops resistance to the antifungal drug amphotericin B (AmB).  This has been puzzling as the drug has been in clinical use for over 50 years. Whitehead Institute scientists have now discovered why.  The genetic mutations that enable certain strains of C. albicans to resist AmB simultaneously render it highly susceptible to environmental stressors and disarm its virulence factors.

Schematic showing nerve cells and person with Parkinson's disease within a yeast cell

Yeast, human stem cells drive discovery of new Parkinson’s disease drug targets

October 24, 2013

Using a discovery platform whose components range from yeast cells to human stem cells, Whitehead Institute scientists have identified a novel Parkinson’s disease drug target and a compound capable of repairing neurons derived from Parkinson’s patients.

Slides of mouse brain tissue from CJD mice that are infected with prions compared to tissue from FFI mice.

New models advance the study of deadly human prion diseases

August 19, 2013

By directly altering the gene coding for the prion protein (PrP), Whitehead Institute researchers have created mouse models of two neurodegenerative prion diseases, each of which manifests in different regions of the brain.  These new models for fatal familial insomnia (FFI) and Creutzfeldt-Jakob disease (CJD) accurately reflect the distinct patterns of destruction caused by the these diseases in humans.  Remarkably, as different as each disease is, they both spontaneously generate infectious prions.

Thwarting protein production slows cancer cells’ malignant march

July 18, 2013

Protein production or translation is tightly coupled to a highly conserved stress response—the heat shock response and its primary regulator, heat shock factor 1 (HSF1)—that cancer cells rely on for survival and proliferation, according to Whitehead Institute researchers. In mouse models of cancer, therapeutic inhibition of translation interrupts HSF1’s activity, dramatically slowing tumor growth and potentially rendering drug-resistant tumors responsive to other therapies.

Model for a function for Mot3 prion switching in teh repiro-fermentative cycle of wine yeasts

Protective prion keeps yeast cells from going it alone

March 28, 2013

A team of scientists from Whitehead Institute and the University of Texas Southwestern Medical Center has added markedly to the job description of prions as agents of change, identifying a prion capable of triggering a transition in yeast from its conventional single-celled form to a cooperative, multicellular structure. This change, which appears to improve yeast’s chances for survival in the face of hostile environmental conditions, is an epigenetic phenomenon—a heritable alteration brought about without any change to the organism’s underlying genome.

Microscope images of samples extracted from cancer tumors and adjacent tissues

Heat-shock factor reveals its unique role in supporting highly malignant cancers

August 2, 2012

Whitehead Institute researchers have found that an ancient, highly conserved cell survival factor drives expression of a specific set of genes that is strongly associated with metastasis and death in patients with breast, colon, and lung cancers.

Schematic diagram of the Hsp90 protein.

Breast cancer clinical trial to test combination of heat shock protein inhibitor and hormonal therapy

May 22, 2012

A clinical trial involving collaboration between researchers at Whitehead Institute and Dana Farber Cancer Institute is now enrolling patients with recurrent or metastatic estrogen receptor-positive (ER+) breast cancer.

Pages

© Whitehead Institute for Biomedical Research              455 Main Street          Cambridge, MA 02142